Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Evaluation of a Novel Molecular NSCLC Classification System|
- Validation of a novel 4-protein signature's ability to subtype NSCLC [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- NSCLC misclassification rate [ Time Frame: 1 month ] [ Designated as safety issue: No ]
|Study Start Date:||October 2011|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
Novel Molecular NSCLC Classification (H & E staining, IHC)
Previously collected tissue samples are analyzed via H&E staining and IHC.
Other: laboratory biomarker analysis
I. To validate a novel 4-protein signature's ability to subtype non-small cell lung cancer (NSCLC) in a treatment-naive, multi-institutional cohort, Cancer and Leukemia Group B (CALGB) 9761.
I. To estimate the NSCLC misclassification rate in a multi-institutional clinical-trial setting for stage 1 NSCLC (adenocarcinoma versus squamous cell).
Previously collected tissue samples are analyzed via hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01415739
|United States, Massachusetts|
|Alliance for Clinical Trials in Oncology|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Daniel J. Boffa, MD||Smilow Cancer Hospital at Yale-New Haven|